Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: judgment (161), prudence (1), caution (124), good judgment (68), maturity (33)

Clarithromycin-Dexamethasone_40_Pomalidomide

Description: Chemotherapy Protocol Myeloma Clarithromycin-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Clarithromycin-Dexamethasone (40)-Poma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Clarithromycin-Dexamethasone-40-Pomalidomide.pdf

Clarithromycin-Dexamethasone_20_Pomalidomide

Description: Chemotherapy Protocol Myeloma Clarithromycin-Dexamethasone (20)-Pomalidomide Regimen • Myeloma – Clarithromycin-Dexamethasone (20)-Poma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Clarithromycin-Dexamethasone-20-Pomalidomide.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Pomalidomide
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Glofitamab-Obinutuzumab

Description: Chemotherapy Protocol LYMPHOMA GLOFITAMAB-OBINUTUZUMAB Regimen • Lymphoma-Glofitamab-Obinutuzumab Indication • Tr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Glofitamab-Obinutuzumab.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

MP000 028 Cellular pathology user handbook v24

Description: University Hospital Southampton NHS Foundation Trust PATHOLOGY DIRECTORATE Cellular Pathology (Management) MP 000 028 Revision 24 P
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Cell-path/MP000-028-Cellular-pathology-user-handbook-v24.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title:
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Papers Trust Board - 10 March 2026

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 10/03/2026 9:00 - 13:00 Conference Room, Heartbeat Education
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Papers-Trust-Board-10-March-2026.pdf

31 to 40 of 137

Previous … 2 3 4 5 6 … Next